2022
DOI: 10.1002/adma.202205324
|View full text |Cite
|
Sign up to set email alerts
|

Edge‐Site Engineering of Defective Fe–N4 Nanozymes with Boosted Catalase‐Like Performance for Retinal Vasculopathies

Abstract: Extensive efforts are devoted to refining metal sites for optimizing the catalytic performance of single‐atom nanozymes (SANzymes), while the contribution of the defect environment of neighboring metal sites lacks attention. Herein, an iron‐based SANzyme (Fe‐SANzyme) is rationally designed by edge‐site engineering, which intensively exposes edge‐hosted defective Fe–N4 atomic sites anchored in hierarchical mesoporous structures. The Fe‐SANzyme exhibits excellent catalase‐like activity capable of efficiently cat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

2
83
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 118 publications
(85 citation statements)
references
References 56 publications
2
83
0
Order By: Relevance
“…Chemically engineering nanomaterials to exert potent anticancer activity, such as radiosensitizing cancer cells, exhausting energy metabolism, and generating reactive oxygen species (ROS), has the promising potential to achieve satisfactory therapeutic outcomes. More recently, inspired by natural metalloenzymes, fine-defined single-atom nanozymes (SAzymes), in which metal atoms as active sites are monodispersed on supports, have drawn significant attention for their ability to trigger abnormally low or high levels of intracellular biomarkers through catalysis to induce cancer-specific cytotoxicity, thereby rapidly emerging as a competitive alternative for therapeutic use in oncology. For instance, oxidoreductase-like SAzymes that respond to the tumor microenvironment enable the conversion of less reactive H 2 O 2 into highly cytotoxic hydroxyl radicals ( • OH) for chemodynamic therapy or into O 2 for overcoming tumor hypoxia toward the following treatments. However, the catalytic active sites of most SAzymes are identified predominantly as their superficial atoms rather than their inner moieties, which severely limits therapeutic efficacy as the result of this deficient catalytic activity. Moreover, intratumoral H 2 O 2 , although it is higher compared to normal cells, remains largely insufficient, thus presenting another challenge to enzymatic therapy owing to H 2 O 2 -dependent • OH generation. In addition, overexpressed glutathione (GSH) can quickly consume • OH produced by SAzymes at the tumor sites, further blunting its anticancer efficacy. …”
mentioning
confidence: 99%
“…Chemically engineering nanomaterials to exert potent anticancer activity, such as radiosensitizing cancer cells, exhausting energy metabolism, and generating reactive oxygen species (ROS), has the promising potential to achieve satisfactory therapeutic outcomes. More recently, inspired by natural metalloenzymes, fine-defined single-atom nanozymes (SAzymes), in which metal atoms as active sites are monodispersed on supports, have drawn significant attention for their ability to trigger abnormally low or high levels of intracellular biomarkers through catalysis to induce cancer-specific cytotoxicity, thereby rapidly emerging as a competitive alternative for therapeutic use in oncology. For instance, oxidoreductase-like SAzymes that respond to the tumor microenvironment enable the conversion of less reactive H 2 O 2 into highly cytotoxic hydroxyl radicals ( • OH) for chemodynamic therapy or into O 2 for overcoming tumor hypoxia toward the following treatments. However, the catalytic active sites of most SAzymes are identified predominantly as their superficial atoms rather than their inner moieties, which severely limits therapeutic efficacy as the result of this deficient catalytic activity. Moreover, intratumoral H 2 O 2 , although it is higher compared to normal cells, remains largely insufficient, thus presenting another challenge to enzymatic therapy owing to H 2 O 2 -dependent • OH generation. In addition, overexpressed glutathione (GSH) can quickly consume • OH produced by SAzymes at the tumor sites, further blunting its anticancer efficacy. …”
mentioning
confidence: 99%
“…Based on the H & E staining result, Fe-SANzyme was suggested as a secure and efficient antioxidant medication of ocular retinopathy. 89…”
Section: Nanozyme In Non-oncologic Therapymentioning
confidence: 99%
“…Based on the H & E staining result, Fe-SANzyme was suggested as a secure and efficient antioxidant medication of ocular retinopathy. 89 As the systemic inflammatory response syndrome, sepsis is one of the oxidation-related inflammatory diseases brought on by microbial infections. Yang et al designed Cu-SAzyme, which demonstrated excellent SOD-mimic properties for O 2 À elimination as well as desirable stability over a broad range of pH and temperature.…”
Section: Nanozyme-related Anti-inflammatory Therapymentioning
confidence: 99%
“…Interestingly, these oxidation reactions are catalyzed by carbon nitrides via different reactive oxygen-related intermediates under similar conditions, except for light irradiation. [45][46][47][48][49] As such, we reason that the multiformity of carbon nitrides in oxidation processes would offer an intriguing way to solve the inconsistency of reaction conditions in realizing the basic activity and the gain effect for self-adaptability; however, to our knowledge, this has rarely been reported.…”
Section: Introductionmentioning
confidence: 99%